Aurinia Pharmaceuticals Inc. (AUPH)
NASDAQ: AUPH · Real-Time Price · USD
9.03
-0.01 (-0.11%)
At close: Dec 20, 2024, 4:00 PM
8.99
-0.04 (-0.44%)
After-hours: Dec 20, 2024, 4:06 PM EST
Aurinia Pharmaceuticals Revenue
Aurinia Pharmaceuticals had revenue of $67.77M in the quarter ending September 30, 2024, with 24.32% growth. This brings the company's revenue in the last twelve months to $220.36M, up 38.72% year-over-year. In the year 2023, Aurinia Pharmaceuticals had annual revenue of $175.51M with 30.95% growth.
Revenue (ttm)
$220.36M
Revenue Growth
+38.72%
P/S Ratio
5.88
Revenue / Employee
$734,537
Employees
300
Market Cap
1.29B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 175.51M | 41.48M | 30.95% |
Dec 31, 2022 | 134.03M | 88.43M | 193.89% |
Dec 31, 2021 | 45.61M | -4.51M | -9.00% |
Dec 31, 2020 | 50.12M | 49.80M | 15,660.38% |
Dec 31, 2019 | 318.00K | -145.00K | -31.32% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AdaptHealth | 3.26B |
Evolent Health | 2.46B |
Alphatec Holdings | 572.74M |
MiMedx Group | 342.80M |
STAAR Surgical Company | 341.22M |
Maravai LifeSciences Holdings | 276.92M |
Day One Biopharmaceuticals | 101.95M |
Ocular Therapeutix | 61.44M |
AUPH News
- 4 weeks ago - Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis - Business Wire
- 5 weeks ago - Aurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of LUPKYNIS® in Managing LN at American College of Rheumatology Convergence 2024 - Business Wire
- 5 weeks ago - Aurinia to Participate in Jefferies London Healthcare Conference - Business Wire
- 6 weeks ago - Aurinia Pharmaceuticals: A Potential Buyout Looms On The Horizon - Seeking Alpha
- 6 weeks ago - Aurinia Pharmaceuticals, Inc. (AUPH) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Aurinia Pharmaceuticals Appoints Craig Johnson to Board of Directors to Support Next Phase of Growth - Business Wire
- 6 weeks ago - Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued LUPKYNIS® Growth and AUR200 Development - Business Wire
- 7 weeks ago - Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 7, 2024 - Business Wire